Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-951 in Cyclic Vomiting Syndrome
NCT06768658Phase 1Terminated
- Sponsor
- Takeda
- Start
- Mar 2022
- Primary completion
- Jan 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-951 in cyclic vomiting syndrome (CVS) (2 arms), sponsored by Takeda. Primary endpoint: Number of Participants Who Experience at Least One Treatment-emergent Adverse Event up to 44 weeks. Started Mar 2022; status: terminated.
02
Drugs
TAK-951
03
Conditions
cyclic vomiting syndrome (CVS)
Beyond the preview
Go deeper on NCT06768658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768658.